Henry Schein, Inc. (NASDAQ:HSIC) Receives $87.85 Consensus Target Price from Analysts

Shares of Henry Schein, Inc. (NASDAQ:HSIC) have earned a consensus rating of “Hold” from the fourteen brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $87.8462.

Several brokerages have recently issued reports on HSIC. BTIG Research raised Henry Schein from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a research note on Thursday, June 11th. Wells Fargo & Company upped their price target on Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 25th. JPMorgan Chase & Co. upped their price target on Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Robert W. Baird set a $97.00 price target on Henry Schein in a research note on Wednesday, May 6th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Henry Schein in a research note on Monday, May 4th.

Insider Activity at Henry Schein

In other Henry Schein news, Director William K. Daniel purchased 10,000 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were bought at an average price of $69.19 per share, with a total value of $691,900.00. Following the completion of the transaction, the director directly owned 20,000 shares in the company, valued at $1,383,800. This trade represents a 100.00% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.89% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Henry Schein

Hedge funds have recently modified their holdings of the business. CYBER HORNET ETFs LLC acquired a new stake in shares of Henry Schein during the second quarter worth about $25,000. MUFG Securities EMEA plc acquired a new stake in shares of Henry Schein during the second quarter worth about $27,000. Flagship Harbor Advisors LLC acquired a new stake in shares of Henry Schein during the fourth quarter worth about $30,000. Federated Hermes Inc. acquired a new stake in Henry Schein in the 4th quarter valued at approximately $32,000. Finally, Los Angeles Capital Management LLC acquired a new stake in Henry Schein in the 4th quarter valued at approximately $37,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Trading Up 3.4%

Shares of HSIC opened at $82.82 on Friday. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 0.59. Henry Schein has a 12-month low of $61.94 and a 12-month high of $89.29. The firm has a market capitalization of $9.43 billion, a PE ratio of 25.02, a price-to-earnings-growth ratio of 1.54 and a beta of 0.82. The stock’s fifty day simple moving average is $76.25 and its 200-day simple moving average is $76.59.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.12. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The business had revenue of $3.37 billion for the quarter, compared to analyst estimates of $3.34 billion. During the same quarter in the prior year, the firm posted $1.15 earnings per share. The firm’s revenue for the quarter was up 6.3% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, research analysts predict that Henry Schein will post 5.32 earnings per share for the current year.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.